Reinsurance Group of America heads into the back half of August with the Street's most bullish voices growing louder — and the company's own executives quietly cashing out.
The analyst story has moved cleanly in one direction. Wells Fargo lifted its target to $291 from $269 this week, the latest in a string of upward revisions that have run from July through the post-Q2 period. JP Morgan raised to $293 from $286 on August 11. Barclays moved to $290 from $278 the day after earnings. Every firm that acted in the past six weeks raised rather than cut, and most maintained Overweight or Outperform ratings. TD Cowen remains the lone dissenter, holding a Hold with a $235 target now sitting below the current price at $244.42. Consensus sits at $266.89 — roughly 9% above where the stock trades today — and the direction of travel from the Street has been consistent since before the Q2 print.
What's changed since the August 12 note is that two senior executives moved in the opposite direction to their analysts. Chief Risk Officer Jonathan Porter sold approximately 16,300 shares across August 11-12, realising close to $4 million in proceeds. EVP Ronald Herrmann sold a further 8,700 shares on August 11 for roughly $2.1 million. The trades carry low individual significance scores, and the 90-day net insider position remains a net purchase of 37,376 shares worth approximately $8.8 million — so the overall insider picture isn't alarming. But concentrated selling from two executives in the days immediately after an earnings pop and a fresh wave of analyst upgrades is worth flagging as a contrasting signal to the bullish consensus.
Positioning in the lending market stays completely relaxed. Short interest has continued its post-earnings retreat, falling a further 33% on the week to 1.18% of free float — extending the decline that was already the story two notes ago. Availability remains effectively unlimited: over 30 million shares are available to borrow against fewer than 800,000 actually shorted. Cost to borrow runs at 0.44%, near the bottom of its 30-day range. There is no short-side friction of any kind, and the ORTEX short score has eased to 29.9 from 32.2 a week ago — a move that confirms bears are not rebuilding.
Options positioning has settled into a more neutral register compared to the elevated put/call ratio flagged after earnings. The PCR is running at 0.37, up from the near-zero readings seen in late July but well below the post-earnings spike. The z-score relative to the 20-day mean has moderated to roughly 0.94 standard deviations — elevated but no longer the sharp divergence from the tape that it was. The pattern suggests the hedging impulse that followed Q2 has partially normalised without fully disappearing.
The next earnings event is scheduled for November 5. Between now and then, the key tension to watch is whether the insider selling proves isolated and routine — consistent with post-earnings award vesting — or widens to include more senior names, which would add weight to the bear case around Asia Pacific headwinds and benefit ratio pressure that analysts are otherwise choosing to look through.
See the live data behind this article on ORTEX.
Open RGA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
